Want to join the conversation?
$LIVN announced long term results from the RESPOND-CRT clinical trial after an 18 month follow-up period. The trial was designed to investigate the clinical efficacy and safety of device-based optimization using $LIVN's proprietary SonR cardiac contractility sensor technology in patients with advanced heart failure.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.